Lymphoproliferative disorders: A comparison of the sensitivity of flow cytometry and bone marrow biopsy in the detection of minimal residual disease in chronic lymphocytic leukemia

Haematologica

Volumn 91, Issue 6, 2006, Pages 860-861

  Maloum, Karim ^a   Charlotte, Frédéric ^a   Divine, Marine ^b   Cazin, Bruno ^c   Lesty, Claude ^a   Merle Béral, Hélène ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Bone marrow biopsy; CLL; Flow cytometry; MRD

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE;

ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MINIMAL RESIDUAL DISEASE; BIOPSY; BONE MARROW CELL; COMPARATIVE STUDY; LETTER; METHODOLOGY; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

BIOPSY; BONE MARROW CELLS; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; NEOPLASM, RESIDUAL; SENSITIVITY AND SPECIFICITY;

EID: 33745754857     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Dighiero G, Maloum K, Desablens B, Cazin B, Navarre M, Leblay R, et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 1998;338:1506-14.
2. Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001;98:29-35.
3. Maloum K, Magnac C, Cazin B, Divine M, Leprêtre S, Delmer A, et al. Predictive value of mutational IgVH gene status for incomplete response and relapse after oral fludarabine phosphate (Fludara® Oral) and Cyclophosphamide. Blood 2003; 102:35a[abstract].
4. Cheson KD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institured-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87: 4990-7.
5. Oudat R, Keating MJ, Lerner S, O'Brien S, Albitar M. Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukaemia patients with nodular partial remission. Leukemia 2002;16:632-5.
6. Cazin B, Maloum K, Divine M, Lepretre S, Travade P, Delmer A, et al. Oral fludarabine and cyclophosphamide in previously untreated CLL: preliminary data on 75 pts. Blood 2002;100: 206a[abstract].
7. + subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia. Br J Haematol 2002;119:970-5.
8. Weiss MA, Glenn M, Maslak P, Rahman Z, Noy A, Zelenetz A, et al. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia 2000;14:1577-82.
9. Moreton P, Kennedy B, Lucas C, Leach M, Rassam SM, Haynes A, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23: 2971-9.